Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Agilon Health ( (AGL) ) has shared an announcement.
On July 29, 2025, Steven J. Sell resigned as CEO and President of Agilon Health, leading to the establishment of an Office of the Chairman and interim executive officers. This leadership change, along with market challenges, prompted Agilon to suspend its 2025 earnings guidance. The company’s second-quarter results showed a 6% revenue decline and significant losses, attributed to market exits and reduced risk adjustment revenue. Agilon continues to focus on strategic initiatives to improve performance and expects to benefit from these efforts in the future.
The most recent analyst rating on (AGL) stock is a Sell with a $2.40 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.
Spark’s Take on AGL Stock
According to Spark, TipRanks’ AI Analyst, AGL is a Neutral.
Agilon Health’s overall stock score reflects significant financial and technical challenges, with low profitability and weak market momentum. While there are positive developments in technology and potential improvements in CMS rates, these are overshadowed by ongoing financial losses and bearish trends.
To see Spark’s full report on AGL stock, click here.
More about Agilon Health
Agilon Health is a company that partners with physicians to transform healthcare through a value-based Total Care Model, focusing on senior patients. It provides technology, capital, and a network of over 2,200 primary care physicians to help physician groups and health systems transition from volume-based to value-based care, aiming to create healthier communities and empowered doctors.
Average Trading Volume: 3,820,854
Technical Sentiment Signal: Sell
Current Market Cap: $703.7M
For an in-depth examination of AGL stock, go to TipRanks’ Overview page.